Archiwa: PDF

Retina Treatment: Subliminal Treatment Procedure by Victor CHONG, MD (UK), Royal Free London NHS Foundation Trust, Optegra Eye Hospital, Central London

Easyret Treatment Guidelines: Multispot mode

Diabetic retinopathy (DR) is a major microvascular complication of diabetes. It is estimated that by 2030, nearly 200 million people will be affected by this disease. During this period, visionthreatening DR will increase from 37 million to 56 million people globally. Center-involved diabetic macular edema (CI-DME) is the most common cause of decreased visual acuity in DR patients, affecting more than 750,000 patients in the United States alone.

In this time of uncertainty, one thing is certain (at least in ophthalmology): Retinal pathologies are not going anywhere. In fact, chronic conditions like age-related macular degeneration (AMD) and diabetic retinopathy (DR) are thought to be causing more concerns during this period of worldwide lockdown and social distancing.

DME is one of the most common causes of sightthreatening retinopathy for people with diabetes, which currently affects more than 30 million people worldwide. As the prevalence of diabetes and vision diseases related to diabetes continues to rise, so does the burden it creates on health care systems.

Patients with center-involved diabetic macular edema (CI-DME) with good visual acuity (VA) represent a controversial clinical scenario in which a subthreshold laser might be a reasonable approach. We report a case series of patients with CI-DME with VA better than 20/32 who were treated with a subthreshold 577 nm (yellow) laser.

Macular laser photocoagulation (MLP) is inferior to intravitreal vascular endothelial growth factor (VEGF) inhibitors in the treatment of center-involved diabetic macular edema (DME). Ultra-widefield fluorescein angiography-guided laser photocoagulation to presumed ischemic areas of the peripheral retina or MLP do not reduce the treatment burden nor improve the visual outcomes of eyes treated with anti-VEGF drugs.

To investigate the effects of subliminal micropulse yellow laser application on the central macular thickness and best-corrected visual acuity in cystoid macular edema secondary to retinitis pigmentosa patients.

Through the years, laser has evolved dramatically. Although intravitreal injections have become the first line of treatment of macular pathologies such as diabetic macular edema (DME), laser application within clinical settings continues to prove efficacious in macular conditions.

Prior to the development of panretinal photocoagulation (PRP) in the 1970s, proliferative diabetic retinopathy (PDR) was the most common cause of blindness in diabetic patients. The diabetic retinopathy study demonstrated that PRP could decrease severe visual loss from PDR by 50%.